Anti-Müller-Hormon (AMH)

Andersen CY, Byskov AG (2006) Estradiol and regulation of anti-Mullerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles‘ fluid. J Clin Endocrinol Metab 91: 4064–4069

Anderson RA, Themmen AP, Al-Qahtani A et al. (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21: 2583–2592

de Vet A, Laven JS, de Jong FH et al. (2002) Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77: 357–362

Elgindy EA, El-Haieg DO, El-Sebaey A (2007) Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril (in press)

Fanchin R, Schonauer LM, Righini C et al. (2003) Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18: 323–327

Feyereisen E, Mendez Lozano DH, Taieb J et al. (2006) Anti-Mullerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online 12: 695–703

Fleming R, Deshpande N, Traynor I, Yates RW (2006) Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 21: 1436–1441

Fraisse T, Ibecheole V, Streuli I et al. (2007) Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil Steril (in press)

Freeman EW, Gracia CR, Sammel MD et al. (2007) Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 87: 101–106

Freour T, Mirallie S, Bach-Ngohou K et al. (2007). Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 375: 162–164

Gustafson ML, Lee MM, Scully RE et al. (1992) Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 326: 466–471

Hazout A, Bouchard P, Seifer DB et al. (2004) Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82: 1323–1329

Kevenaar ME, Themmen AP, Rivadeneira F et al. (2007) A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod 22: 2382–2388

La Marca A, Giulini S, Orvieto R et al. (2005) Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 20: 1569–1572

La Marca A, Malmusi S, Giulini S et al. (2004) Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19: 2738–2741

La Marca A, Stabile G, Artenisio AC, Volpe A (2006) Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21: 3103–3107

La Marca A, Volpe A (2007) The Anti-Mullerian hormone and ovarian cancer. Hum Reprod Update 13: 265–273

Lane AH, Lee MM, Fuller AF et al. (1999) Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 73: 51–55

Laven JS, Mulders AG, Visser JA et al. (2004) Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89: 318–323

Lee MM, Donahoe PK (1993) Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 14: 152–164

Long WQ, Ranchin V, Pautier P et al. (2000) Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 85: 540–544

Nakhuda GS, Sauer MV, Wang JG et al. (2007) Mullerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF. Reprod Biomed Online 14: 450–454

Nelson SM, Yates RW, Fleming R (2007) Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles – implications for individualization of therapy. Hum Reprod 22: 2414–2421

Pigny P, Jonard S, Robert Y, Dewailly D (2006) Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91: 941–945

Rey RA, Lhomme C, Marcillac I et al. (1996) Antimullerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol 174: 958–965

Seifer DB, MacLaughlin DT, Christian BP et al. (2002) Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77: 468–471

Somunkiran A, Yavuz T, Yucel O, Ozdemir I (2007) Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 134: 196–201

Streuli I, Fraisse T, Pillet C et al. (2007) Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril (in press)

Teixeira J, Maheswaran S, Donahoe PK (2001) Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 22: 657–674

Thum MY, Abdalla HI, Taylor D (2007) Relationship between women’s age and basal follicle-stimulating hormone levels with aneuploidy risk in in vitro fertilization treatment. Fertil Steril (in press)

Tsepelidis S, Devreker F, Demeestere I et al. (2007) Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 22: 1837–1840

van Beek RD, van den Heuvel-Eibrink MM, Laven JS et al. (2007) Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab 92: 3869–3874

van der Steeg JW, Steures P, Eijkemans MJ et al. (2007) Predictive value and clinical impact of Basal follicle-stimulating hormone in subfertile, ovulatory women. J Clin Endocrinol Metab 92: 2163–2168

van Rooij I, Broekmans FJ, Scheffer GJ et al. (2005) Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83: 979–987

van Rooij I, Broekmans FJ, Te Velde ER et al. (2002) Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17: 3065–3071

Wachs DS, Coffler MS, Malcom PJ, Chang RJ (2007) Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab 92: 1871–1874

Wunder DM, Bersinger NA, Yared M et al. (2007) Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril (in press)